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Oxidized Low-Density Lipoprotein, Statin Therapy,
Quantitative Coronary Angiography, and Atheroma Volume
Observations From the REVERSAL (Reversal
of Atherosclerosis with Aggressive Lipid Lowering) Study
Seung Hyuk Choi, MD,*§ Andrew Chae, BS,§ Elizabeth Miller, BS,§ Michael Messig, PHD,†
Fady Ntanios, PHD,† Anthony N. DeMaria, MD, MACC,§ Steven E. Nissen, MD, FACC,*
Joseph L. Witztum, MD,§ Sotirios Tsimikas, MD, FACC§
Seoul, Korea; New York, New York; Cleveland, Ohio; and San Diego, California
Objectives This study was designed to test the hypothesis that circulating biomarkers of oxidized low-density lipoprotein
(OxLDL) are affected by statin therapy and predict changes in atheroma volume.
Background Oxidative stress is thought to play an important role in atherogenesis but the relationship between OxLDL, statin
therapy, and atheroma volume in humans is not known.
Methods In a subgroup of 214 patients from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering)
trial, oxidized phospholipids (OxPL) and malondialdehyde (MDA) epitopes per apolipoprotein B-100 (apoB), im-
munoglobin (Ig) G and IgM apoB immune complexes, and OxLDL autoantibodies were measured at baseline and
after 18 months of treatment with atorvastatin or pravastatin. Relationships between changes of OxLDL bio-
markers and quantitative coronary angiography (QCA), total atheroma volume, and percentage atheroma
volume were analyzed.
Results There were no differences in QCA parameters or atheroma volume in the 2 groups at baseline. Compared with
baseline values, OxPL/apoB and MDA/apoB, and lipoprotein (a) levels increased 21% to 48% (p  0.001 for all)
in response to atorvastatin and 17% to 39% (p  0.001 for all) in response to pravastatin. In contrast, IgG apoB
immune complexes, IgM apoB immune complexes, and IgM OxLDL autoantibodies were significantly reduced by
both atorvastatin and pravastatin (p value range 0.003 to 0.001). There were no significant differences be-
tween the atorvastatin and pravastatin groups. In the entire cohort, there were no correlations between changes
in any OxLDL biomarkers and changes in QCA parameters or atheroma volume.
Conclusions Statin therapy results in significant increases in OxPL/apoB, MDA/apoB, and lipoprotein (a) levels and decreases
in apoB immune complexes and OxLDL autoantibodies. However, these measures did not correlate with changes
in QCA parameters or atheroma volume. (J Am Coll Cardiol 2008;52:24–32) © 2008 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.02.066u
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July 1, 2008:24–32 Plasma Oxidized Phospholipids and IVUSnd qualitative changes of atherosclerotic lesions would
rovide useful tools to assess effects of statin therapy on
egression of atherosclerosis.
Oxidized low-density lipoprotein (OxLDL) is primarily
resent in the vessel wall and has proatherogenic and proin-
ammatory properties (5,6). One marker of oxidative stress is
he content of oxidized phospholipids (OxPL) on apolipopro-
ein B-100 particles (OxPL/apoB). Increased levels of
xPL/apoB are positively associated with angiographically
efined coronary artery disease (7), progression of carotid
nd femoral atherosclerosis (8), and prediction of new
ardiovascular events (9). Several studies have demonstrated
cute transient increases of OxPL/apoB levels in patients
ith acute coronary syndromes and after percutaneous
oronary intervention (PCI), situations where one may
ropose plaque rupture resulting in release of plaque oxidized
ipids into the circulation (10,11). Other biomarkers of
xLDL, such as apolipoprotein B-100-immune complexes
apoB-IC) or autoantibodies to specific epitopes of OxLDL,
ave been associated, albeit less consistently and not always
ndependently, with atherosclerosis (12,13).
Interestingly, in studies done to date, OxPL/apoB levels
lso increase in response to low-fat diets in animals and
umans or in response to statin therapy in humans, but at a
lower rate than in acute coronary syndromes or PCI
14–17), consistent with a flux of such particles from the
essel wall to the vessel lumen. In this study, we hypothe-
ized that statin-induced changes in OxLDL biomarkers
ay reflect changes in QCA parameters of atheroma vol-
me measured by IVUS.
ethods
atient population and blood samples. The REVERSAL
Reversal of Atherosclerosis with Aggressive Lipid Lower-
ng) trial enrolled 502 patients ages 30 to 75 years who
equired coronary angiography for a clinical indication and
emonstrated at least 1 obstruction with angiographic
uminal diameter narrowing of 20% to 60% (3). Patients
ere randomly assigned to either atorvastatin 80 mg or
ravastatin 40 mg daily in a blinded fashion. After the
8-month treatment period, patients underwent repeat
oronary angiography and IVUS examination of the
atched segments under identical conditions. Of the 502
atients in the REVERSAL study, 214 (43% of the
EVERSAL population) had available baseline and end-
f-study blood samples and complete IVUS data and,
herefore, composed the study group. The blood samples
ere placed in tubes containing ethylenediaminetetracetic
cid, shipped on ice overnight to a central laboratory,
ivided into aliquots, and stored at 70°C until shipping to
r. Tsimikas’s laboratory. Previous studies have shown
hat shipping samples on ice (Online Table 1) prolonged
torage (5 years) and several freeze-thaw cycles do not
ffect the OxLDL measures used in this study (8,16).
he Human Subjects Protection Program at the Univer- dity of California–San Diego ap-
roved research using these
lood samples.
ngiographic and IVUS analy-
is. The acquisition and mea-
urement methodology of QCA
nd IVUS images used in the
EVERSAL study has been
reviously described in detail (3).
theroma area was determined
s the difference between exter-
al elastic membrane (EEM)
nd lumen areas. Total atheroma
olume (TAV) was calculated as
he sum of differences between
EM and lumen areas across all
valuable slices (i.e., total ather-
ma volume   [EEM area 
umen area]) and atheroma vol-
me in the most diseased seg-
ent was defined as TAV in the
0-mm subsegment of the coro-
ary artery with the greatest
laque volume at baseline. Per-
ent atheroma volume (PAV)
as calculated as the percentage
f the sum of EEM areas that
as occupied by TAV (PAV 
 (EEM area  lumen area)/
EEM area)]  100). Arterial
all remodeling was assessed by
omparing the EEM area at the
esion and reference sites. For
erial assessment of remodeling,
he remodeling index was de-
ned as the change in EEM
rom baseline to month 18 di-
ided by the change in TAV from baseline to month 18.
sing this approach, for regressing plaques, a ratio 1 was
onsidered expansive, 0 to 1 as incomplete, and 0 as
onstrictive remodeling (18).
etermination of OxLDL biomarkers: OxPL/apoB,
DA/apoB, apoB-IC, and IgG MDA-LDL autoanti-
ody titers. OxPL/apoB was measured as described in
etail previously (7,15) by chemiluminescent enzyme-linked
mmunosorbent assay using the murine monoclonal anti-
ody E06, which binds to the phosphorylcholine head
roup of oxidized but not native phospholipids. In brief, a
:50 dilution of plasma was added to microtiter wells coated
ith the murine monoclonal antibody MB47 (5 g/ml),
hich specifically binds apoB. Under these conditions, a
aturating amount of apoB is added to each wall, and
onsequently, equal numbers of apoB particles were cap-
ured in each well for all samples. The content of OxPL/
poB is then determined with biotinylated E06, and the
Abbreviations
and Acronyms
apoB  apolipoprotein
B-100
apoB-IC  apolipoprotein
B-100-immune complexes
EEM  external elastic
membrane
hsCRP  high sensitivity
C-reactive protein
IC/apoB  immune
complexes per
apolipoprotein B-100
Ig  immunoglobin
IVUS  intravascular
ultrasound
Lp(a)  lipoprotein(a)
MDA  malondialdehyde
MDA/apoB 
malondialdehyde epitopes
per apolipoprotein B-100
OxLDL  oxidized low-
density lipoprotein
OxPL  oxidized
phospholipids
OxPL/apoB  oxidized
phospholipid epitopes per
apolipoprotein B-100
PAV  percentage change
in atheroma volume
PCI  percutaneous
coronary intervention
QCA  quantitative
coronary angiography
TAV  total atheroma
volumeata are presented as relative light units per 100 ms. Thus,
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Plasma Oxidized Phospholipids and IVUS July 1, 2008:24–32y design, the OxPL/apoB measurement is independent of
poB (and LDL cholesterol) levels (8,15).
In a very similar fashion to our OxPL/apoB calculations,
e also measured malondialdehyde (MDA) epitopes on
poB particles (MDA/apoB) using the well-characterized
urine monoclonal antibody MDA2 (19,20), which binds
DA-lysine epitopes. In this assay, unlabeled MDA2
as added to the plates after apoB was captured, and the
mount of MDA2 bound was detected with an alkaline
hosphatase-labeled goat antimouse immunoglobin
Ig)G antibody.
Chemiluminescence enzyme-linked immunosorbent as-
ays were also used to measure IgG and IgM autoantibodies
o MDA-LDL and apoB-IC as described previously (13).
he data for apoB-IC are presented in 2 ways: 1) as
mmune complexes per apolipoprotein B-100 (IC/apoB),
hich specifically quantify the content immune complexes
n each captured apoB particle; and 2) as total apoB-IC,
hich reflects the IC content on all apoB-containing
articles in plasma, by multiplying the plasma IC/apoB
alue by the plasma apoB levels measured independently by
outine methods as noted. The intra-assay coefficients of
ariation for all assays were 6% to 10%.
ipoprotein (a) [Lp(a)] and apoB levels. Plasma Lp(a)
evels were measured by a chemiluminescent enzyme-linked
mmunosorbent assay with monoclonal antibody LPA4, as
escribed previously (11). In this assay, apoB is captured and
iotinylated LPA4 is added to detect apo(a). apoB levels
ere measured by a commercial kit (Diasorin Inc., Saluggia,
taly).
tatistical analysis. The OxLDL markers were log-
ransformed for analysis and back-transformed to yield
eometric means and 95% confidence intervals (CIs) for
aseline and percentage changes from baseline to month 18.
ipid measures at baseline and month 18 (expressed as
ercentage changes from baseline) were analyzed on their
riginal scale. Inferential analyses of OxLDL markers and
ipids were based on paired t tests for within treatment
omparisons and 2-sample t tests for between treatment
omparisons. Medians and 95% CIs were presented for the
ngiographic measures. Inferential analyses for the angio-
raphic measures were based on the sign test for within-
reatment comparisons and ranked-transformed analysis of
ovariance, with model terms for treatment group and the
anked-transformed baseline angiographic measure as a
ovariate, for between treatment comparisons (ranked-
ransformed analysis of variance was used for the remodel-
ng index). All p values were 2-sided with p  0.05
onsidered significant.
For a further description of bivariate relationships with
ltrasonographic end points, we used the locally weighted
catter plot smoothing technique. This technique is de-
igned to produce a smooth fit to the data and reduces the
nfluence of extreme outliers. wesults
atient characteristics and baseline OxLDL biomarkers.
aseline clinical characteristics of this study population were
imilar between groups (Table 1) and similar to those of the
ntire REVERSAL population. Baseline levels of lipid
ariables and OxLDL biomarkers including OxPL/apoB,
DA/apoB, Lp(a), total apoB-IC, IC/apoB, and autoan-
ibodies to MDA-LDL were similar between groups.
ngiographic and IVUS measurements in the atorvasta-
in and pravastatin groups. There were no differences in the
ercent diameter stenosis, minimal lumen diameter, or the
aximal lumen diameter between the atorvastatin and prava-
tatin groups (Table 2). Similarly, there were no differences
etween groups in TAV, PAV, or atheroma volume in the
ost diseased segment. Significant between-group differences
ere observed in the nominal change in PAV (1.29 in
ravastatin vs. 0.11 in atorvastatin, p  0.01), consistent with
he primary end point of the overall REVERSAL results
Table 3).
he effect of statin therapy on lipid parameters, OxLDL
iomarkers, and Lp(a). The influence of statin therapy
n lipid parameters was consistent with the findings in
he overall trial (Fig. 1). Compared with their respective
aseline levels, levels of OxPL/apoB, MDA/apoB, and
p(a) at 18 months were significantly increased in both
he atorvastatin group (48%, 21%, and 14%, respectively;
 0.001 for all) and pravastatin group (39%, 22%, and
4%, respectively; p  0.001) (Fig. 2). A sensitivity
nalysis was performed on the relationship of OxPL/
poB to Lp(a) by analyzing the results as a percentage
hange in median values: pravastatin 40 mg (OxPL/apoB
32.7 [95% CI: 22.9 to 46.0], p  0.001; Lp(a)  25.1
95% CI: 13.2 to 33.0], p  0.001); atorvastatin 80 mg
OxPL/apoB  58.4 [95% CI: 30.1 to 78.3], p  0.001;
p(a)  31.2 [95% CI: 14.8 to 39.1], p  0.001). The
esults are quite similar to the main findings and are not
nfluenced by outliers.
Total IgG and IgM apoB-IC, IgG and IgM IC/apoB,
nd IgM MDA-LDL autoantibodies were significantly
educed in response to both atorvastatin and pravastatin
p value range 0.003 to 0.001). There were significant
eductions in Total IgG and IgM apoB-IC levels in the
torvastatin group compared with the pravastatin group
p  0.001). However, there were no significant differ-
nces between the atorvastatin and pravastatin groups in
he percent change of OxPL/apoB, MDA/apoB, Lp(a),
gG and IgM IC/apoB, or IgG and IgM MDA-LDL
utoantibodies.
elationship between the OxLDL biomarker levels and
theroma volume. There were no significant correlations
etween the change in QCA parameters, TAV, or PAV
ith changes in levels of OxPL/apoB, MDA/apoB, and
p(a) levels or in the change in TAV or change in
xLDL biomarkers (Fig. 3). Similarly, no relationships
ere noted between LDL cholesterol, HDL cholesterol,
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July 1, 2008:24–32 Plasma Oxidized Phospholipids and IVUSigh sensitivity C-reactive protein (hsCRP), or other
xLDL biomarkers and QCA or IVUS measures of
theroma burden.
Baseline Characteristics, Lipid, Oxidation,and Biochemical Parameters of the Patient Grou
Table 1 Baseline Characteristics, Lipid, Oxiand Biochemical Parameters of the
Pra
Patient demographics
Age (yrs), mean  SD
BMI (kg/m2), mean  SD
Men, n (%)
White, n (%)
Prior statin use, n (%)
CV risk factors, n (%)
Hypertension, n (%)
Metabolic syndrome, n (%)
Current smoker, n (%)
Diabetes, n (%)
Lipids (mg/dl), mean (95% CI)
Total cholesterol
LDL-C
HDL-C
Triglycerides
apoB
OxLDL biomarkers (RLU), geometric mean (95% CI)
OxPL/apoB
MDA/apoB
Lp(a) (mg/dl)
IC/apoB IgG
IC/apoB IgM
Total apoB-IC IgG* 55
Total apoB-IC IgM* 81
MDA-LDL IgG
MDA-LDL IgM 2
hsCRP (mg/l)
*Total apoB-IC IgG and IgM units are expressed as RLU · mg/dl.
apoB  apolipoprotein B-100; apoB-IC  apolipoprotein B-100 im
cardiovascular; HDL-C  high-density lipoprotein cholesterol; hsCRP
apolipoprotein B-100; Ig immunoglobin; LDL-C low-density lipopro
malondialdehyde epitopes per apolipoprotein B-100; OxLDL oxidi
apolipoprotein B-100; RLU  relative light units.
aseline Angiographic andVUS Parameters in the 2 Groups
Table 2 Baseline Angiographic andIVUS Parameters in the 2 Groups
Median (95% CI)
Pravastatin
40 mg (n  108)
Atorvastatin
80 mg (n  106)
QCA
Percent diameter stenosis 39.4 (35.0–41.2) 37.2 (34.1–45.2)
Minimum lumen diameter (mm) 2.00 (1.86–2.12) 2.01 (1.86–2.09)
Maximum lumen diameter (mm) 3.25 (3.12–3.34) 3.22 (3.14–3.44)
IVUS
Total atheroma volume (mm3) 162 (147–187) 142 (128–165)
Percent atheroma volume 38.9 (37.0–41.2) 37.6 (35.8–40.0)
Atheroma volume in most diseased
segment (mm3)
66.0 (60.3–72.7) 63.4 (59.1–67.4)a
I  confidence interval; IVUS  intravascular ultrasound; QCA  quantitative coronary
ngiography.orrelation between OxPL/apoB levels and Lp(a). Base-
ine plasma OxPL/apoB levels strongly correlated with
aseline plasma Lp(a) levels (r  0.83, p  0.001) in the
ntire cohort of patients (Fig. 4). Interestingly, there was an
nverse correlation between MDA/apoB levels and Lp(a)
evels (r  0.53, p  0.001) (Fig. 4). There was also an
nverse association between OxPL/apoB and MDA/apoB
r  0.44, p  0.001). Similar results were present at the
8-month point (OxPL/apoB and Lp(a), r 0.86, p 0.001;
DA/apoB levels and Lp(a) levels, r0.59, p 0.001; and
xPL/apoB and MDA/apoB levels, r  0.52, p  0.001).
here were no significant correlations between the remain-
ng biochemical variables.
orrelation between hsCRP and OxLDL biomarkers.
t baseline, a weak inverse correlation was noted between
sCRP and Lp(a) (Table 4). When evaluating the data as
he percentage change in hsCRP and OxLDL biomarkers,
here was no correlation between hsCRP and either OxPL/
n,
nt Groups
tin 40 mg (n  108) Atorvastatin 80 mg (n  106)
56.3  9.6 55.9  10.0
30.2  5.4 30.9  7.1
79 (73) 76 (72)
95 (88) 97 (92)
29 (27) 21 (20)
76 (70) 73 (69)
44 (41) 45 (42)
28 (26) 29 (27)
23 (21) 18 (17)
(223–236) 231 (224–237)
(143–153) 151 (145–156)
(40.5–44.6) 43.2 (41.3–45.1)
(174–213) 185 (170–198)
(147–156) 151 (146–155)
(4,125–6,650) 4,243 (3,313–5,433)
(295–481) 380 (304–472)
(6.21–10.6) 6.61 (5.03–8.68)
(3,471–3,994) 3,662 (3,437–3,900)
(4,945–6,028) 5,228 (4,745–5,760)
(518,214–601,375) 546,122 (510,292–584,466)
(738,194–907,849) 779,771 (701,358–866,949)
(5,318–6,974) 5,281 (4,632–6,020)
(20,301–25,527) 22,240 (20,072–24,641)
(2.39–3.52) 2.67 (2.15–3.30)
omplexes; BMI  body mass index; CI  confidence interval; CV 
h sensitivity C-reactive protein; IC/apoB  immune complexes per
lesterol; Lp(a) lipoprotein (a); MDAmalondialdehyde; MDA/apoB
-density lipoprotien; OxPL/apoB oxidized phospholipid epitopes perps
datio
Patie
vasta
230
149
42.6
194
152
5,238
377
8.14
3,723
5,460
8,248
8,639
6,090
2,765
2.90
mune c
 hig
tein cho
zed lowpoB, MDA/apoB, or Lp(a), but there was a correlation of
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Plasma Oxidized Phospholipids and IVUS July 1, 2008:24–32sCRP with IC/apoB IgM and total levels of both IgG and
gM immune complexes.
iscussion
his study tested the hypothesis that statin therapy
ould result in changes in OxLDL biomarkers and that
hese changes would be reflected in QCA parameters of
umen dimensions and IVUS-derived measures of ather-
ma volume. Indeed, it was demonstrated that statin
herapy significantly increased the content of OxPL/apoB
nd MDA/apoB on the remaining plasma apoB particles
n the setting of an overall decrease in apoB levels.
urthermore, levels of apoB-IC and IgM autoantibodies
o OxLDL were significantly reduced with statin therapy.
owever, no differences were noted between the atorva-
tatin and pravastatin groups and these changes in
xLDL biomarkers did not reflect the changes in QCA
arameters or atheroma volume.
Figure 1 Statins and Lipid Parameters
The influence of statin therapy on lipid parameters. ApoB  apolipoprotein B-100;
CI  confidence interval; HDL-C  high-density lipoprotein cholesterol; LDL-C  low
hange in QCA Parameters, Atheroma Volume, and Remodeling Ind
Table 3 Change in QCA Parameters, Atheroma Volume, and Re
Prav
Median (
QCA
Nominal change in percent diameter stenosis 1.46 (2.2
% change in minimum lumen diameter 2.78 (0.00
% change in maximum lumen diameter 0.28 (0.9
IVUS
% change in total atheroma volume 0.90 (4.4
Nominal change in percent atheroma volume 1.29 (0.2
% change in atheroma volume in most diseased segment 3.05 (6.3
Serial remodeling index 1.00 (0.66
Within-group p values. †p  0.01 between groups.
Abbreviations as in Table 2.OxLDL and oxidation-specific epitopes are primarily
resent in atherosclerotic lesions but not normal arteries and
re associated with increased plaque inflammation and
eatures of plaque vulnerability (5,21–23). It has also been
emonstrated that depletion of OxLDL in atherosclerotic
ortic plaques may occur following low-fat, low-cholesterol
iets in LDL receptor(/) mice (24), New Zealand
hite Rabbits (25), and cynomolgus monkeys (17). In
hese studies, it was documented that both OxPL/apoB (17)
nd MDA/apoB epitopes (24,25) were removed from ath-
rosclerotic plaques, as documented by immunostaining,
ollowing the low-fat, low-cholesterol diet, and in higher
roportion to removal of apoB. Interestingly, this occurred
elatively quickly (i.e., within 6 months) and prior to
ignificant decreases in plaque burden. Furthermore, con-
omitant with the reduction in oxidation-specific epitopes,
here was also reduction in reactive oxygen species and
vidence of a change in the plaque characteristics, where
ity lipoprotein cholesterol.
8 Months After Statin Therapy in the 2 Groups
ling Index 18 Months After Statin Therapy in the 2 Groups
40 mg (n  108) Atorvastatin 80 mg (n  106)
I) p Value* Median (95% CI) p Value*
0.33) 0.009 0.65 (1.89 to 0.78) 0.627
) 0.064 1.75 (0.38 to 2.87) 0.030
05) 0.624 1.11 (0.00 to 1.99) 0.095
33) 0.923 1.03 (3.62 to 1.82) 0.771
70)† 0.211 0.11 (1.25 to 0.59) 0.923
63) 0.149 4.56 (8.55 to0.90) 0.019
) — 0.76 (0.39 to 0.91) —-densex 1
mode
astatin
95% C
7 to
to 3.72
4 to 1.
3 to 5.
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July 1, 2008:24–32 Plasma Oxidized Phospholipids and IVUSipid-rich, macrophage-rich plaques were converted to a
ore stable phenotype, with increases in smooth muscle
ells and collagen and decreases in macrophages. In human
tudies, Crisby et al. (26) have shown that immunostaining
or oxidation-specific epitopes present in carotid plaques
as significantly reduced following 3 months of treatment
ith pravastatin prior to carotid endarterectomy. Therefore,
strong rationale exists to suggest that oxidation-specific
pitopes may be viable targets to follow within atheroscle-
otic lesions following therapeutic interventions.
Figure 2 Statins and Biomarkers
The influence of statin therapy on plasma oxidized low-density lipoprotein (OxLDL)
B-100 immune complexes; CI  confidence interval; IC/apoB  immune complexe
dialdehyde; MDA/apoB  malondialdehyde epitopes per apolipoprotein B-100; Ox
Figure 3 Atheroma Volume and Oxidation-Specific Epitopes
Locally weighted scatter plots showing the relationship between the percentage ch
Lp(a) in the 214 patients. In each plot, the solid line represents the point estimatThe link between circulating OxLDL biomarkers, which
eflect the global extent of atherosclerosis, and changes in
therosclerotic plaques in specific regions of interest, is less
ell established. In regression studies in cynomolgus mon-
eys and New Zealand White rabbits that had established
therosclerosis, increases in plasma OxPL/apoB levels (50%
o 100%) were observed following 6 months of low-fat,
ow-cholesterol regression diets, which were associated with
educed OxPL/apoB content in aortic atherosclerotic
laques, suggesting efflux of OxPL/apoB from the vessel
rkers and high sensitivity C-reactive protein (CRP). apoB-IC  apolipoprotein
apolipoprotein B-100; Ig  immunoglobin; Lp(a)  lipoprotein (a); MDA  malon-
B  oxidized phospholipid epitopes per apolipoprotein B-100.
in atheroma volume and the percentage change in OxPL/apoB, MDA/apoB, and
the dashed lines the 95% confidence intervals. Abbreviations as in Figure 2.bioma
s per
PL/apoange
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Plasma Oxidized Phospholipids and IVUS July 1, 2008:24–32all into the lumen (17). In humans, at least those recog-
ized by antibody E06, increases in OxPL/apoB ranging
rom 9% to 48% have been noted following either low-fat
iets or atorvastatin and pravastatin therapy (14–16). In
hese human studies, the increase in OxPL/apoB occurred
oncomitantly with increases in Lp(a) levels, which bind most
f OxPL/apoB in human plasma (7,8,10,11,15,16,27,28). It is
ossible that Lp(a) levels may increase in response to statins
nd ultimately bind OxPL/apoB, which may be released
ndependently. For example, in a study of patients under-
oing PCI (11), a significant increase in OxPL/apoB and
p(a) occurred immediately after PCI, which is consis-
ent with release from the plaque due to plaque disrup-
ion. In the post-PCI time frame, only 50% of the
xPL/apoB were present on Lp(a), whereas the other
0% were on non-Lp(a) apoB particles. However, by 6 h,
he vast majority of OxPL/apoB were physically present
n Lp(a), which is consistent with a net transfer of
xPL/apoB to Lp(a). However, this phenomenon also
Figure 4 Relationship of Lp(a) to Oxidation-Specific Epitopes
Spearman correlations between baseline levels of Lp(a) with OxPL/apoB and Lp(a)
Dashed lines represent the 95% confidence interval. RLU  relative light units; oth
orrelations Between hsCRP and OxLDL Biomarkers
Table 4 Correlations Between hsCRP and OxLDL Biomarkers
OxLDL
Biomarker
Baseline Values
Percentage Change
From Baseline
r Value p Value r Value p Value
OxPL/apoB 0.09 0.18 0.02 0.77
MDA/apoB 0.10 0.14 0.06 0.34
Lp(a) 0.17 0.011 0.01 0.15
IC/apoB IgM 0.002 0.97 0.20 0.005
IC/apoB IgG 0.03 0.67 0.04 0.59
Total apoB-IC IgG 0.03 0.67 0.32 0.0001
Total apoB-IC IgM 0.04 0.52 0.22 0.0008
MDA-LDL IgG 0.13 0.058 0.10 0.16
MDA-LDL IgM 0.13 0.052 0.10 0.15tDL  low-density lipoprotein; other abbreviations as in Table 1.ccurs in New Zealand White rabbits, which do not have
p(a), as well as in cynomolgus monkeys, whose Lp(a) is
ot associated with increased binding of OxPL/apoB.
his suggests that Lp(a) may be the ultimate acceptor of
uch OxPL/apoB in humans, but is not needed to
ediate changes in OxPL/apoB following therapeutic
nterventions.
Although the mechanisms underlying these changes in
xPL/apoB in response to therapeutic interventions have
ot been fully delineated, it is possible that enhancement of
he antiatherogenic functions of HDL may lead to increased
xPL/apoB efflux (6). Consistent with this potential mech-
nism, apo A-I mimetic peptides promote OxPL/apoB
fflux from macrophages to pre-beta HDL in vitro (29) and
po A-I Milano infusion produced a decrease in atheroma
olume in only 5 weeks of therapy (30).
In the present study, the change in OxLDL biomarkers
evels did not predict changes in QCA parameters or
oronary atheroma volume. These findings may simply
eflect the fact that these OxLDL biomarkers do not reflect
CA or IVUS measured changes in atheroma burden in
esponse to statins. There are several other potential expla-
ations for these findings. First, changes in these biomark-
rs may represent the entire atherosclerotic process, which
ay not be entirely reflected in the coronary arteries, that
ould compose a very small portion of atherosclerotic
urden. Second, changes in OxPL/apoB levels may reflect
arly changes in atheromatous plaque composition, which
ccur even before physical plaque regression, as supported
y the findings noted previously in animal models, and
herefore, the changes in atheroma volume noted with
VUS may not be sensitive enough to detect this. Third, the
hange in OxLDL biomarker levels may be attenuated at
DA/apoB.
reviations as in Figure 2.and M
er abbhe later phases of statin therapy, compared with the levels
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July 1, 2008:24–32 Plasma Oxidized Phospholipids and IVUSn the earlier phases. Because serial samples were not
vailable in this study, it is possible that the peak in changes
n these OxLDL biomarkers was missed. Finally, it is
ossible that fundamental antiatherogenic changes did oc-
ur in the vessel wall but that the current IVUS methodol-
gy cannot adequately characterize plaque characteristics
uch as the lipid content. Newer imaging modalities, such as
virtual histology,” integrated backscatter analysis, wavelet
nalysis, and palpography (31,32), and molecular imaging
pproaches may be able to characterize various histologic
omponents of atherosclerotic lesions, but full validation in
atients is pending (33,34).
The present study revealed significant elevations of Lp(a)
evels in response to both statins, and a strong correlation
as noted between OxPL/apoB and Lp(a), which is con-
istent with previous observations (7,8,10,11,14–16). It has
een previously postulated that Lp(a) may function at a
rimordial level to bind and perhaps mediate the removal of
xidized fatty acids from OxPL/apoB, particularly as it is
nriched in lipoprotein-associated phospholipase A2, an
nzyme with the ability to hydrolyze oxidized fatty acids
rom OxPL/apoB (35). However, patients with persistently
igh Lp(a) (36), which has a strong predilection for binding
o matrix components of the vessels wall, are at increased
isk of cardiovascular disease and development of new
ardiac events, such as death, myocardial infarction, and
troke, a relationship which seems to be accentuated by
ncreased Lp-PLA2 activity (9).
In this study, we also report for the first time results of a
ovel assay that measures MDA epitopes on apoB particles.
imilar to the changes in OxPL/apoB levels, MDA/apoB
evels also increased with both statins, although not to the
ame extent, and changes were similar between atorvastatin
nd pravastatin. These results need to be validated in other
tudies, but it may reflect a similar phenomenon to the
xPL/apoB changes. Of further interest, MDA/apoB lev-
ls were inversely associated with Lp(a) levels, suggesting
hat MDA/apoB epitopes are not present on Lp(a), unlike
xPL/apoB, which are present almost exclusively on Lp(a).
tudy limitations. Limitations of this study include the
act that only a subgroup of the REVERSAL population
214 of 502 patients) was available and that only baseline
nd end-of-study blood samples but no interim samples
ere available for analysis. Additionally, in this subgroup of
atients, only the nominal change in PAV, and not TAV,
as significantly different between statin groups, which
long with the modest changes in measures of atheroma
olume may have limited power to see relationships with
xLDL biomarkers.
onclusions
his study demonstrates that statin therapy results in
ignificant increases in OxPL/apoB and MDA/apoB levels,
n parallel with similar increases in Lp(a) levels, and in
ignificant reductions in apoB-IC and autoantibodies toxLDL. However, these changes did not correlate with the
hanges in QCA parameters or atheroma volume measured
y IVUS. Prospective studies are needed to assess whether
hanges in plasma OxLDL biomarkers predict statin-
nduced early changes in plaque characteristics using novel
maging modalities that are capable of quantitating specific
laque characteristics and whether these changes predict
linical benefit.
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